Steroid-Refractory Graft-Versus-Host Disease

The FDA granted fast track designation to neihulizumab for treatment of steroid-refractory acute graft-versus-host disease according to the agent’s manufacturer.

Antithymocyte globulin decreased incidence of acute graft-versus-host-disease after allogeneic stem cell transplantation from an HLA-matched sibling donor, according to randomized study results published in Journal of Clinical Oncology.